Our findings are in line with results from a recent phase IIa trial of anti-IL-20 in RA, where autoantibody-positive patients showed a better response to the anti-IL-20 antibody compared with seronegative patients [28]. This evidence concerns the gene IL20 and rheumatoid arthritis.